Sutro Biopharma

Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009.[1]

Sutro Biopharma
TypePublic
Nasdaq: STRO
Russell 2000 Index component
IndustryBiotechnology
Founded2003 Edit this on Wikidata
HeadquartersSouth San Francisco
Number of employees
290
Websitesutrobio.com

Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

To date, Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.

Technology

Sutro's Xpress CF Platform[2] is based on Stanford Professor James R. Swartz's patented Open Cell-Free Synthesis (OCFS) technology.[3] XpressCF technology enables the parallel expression of hundreds of protein variants in less than 24 hours, providing a platform for the discovery and development of a wide variety of protein classes including cytokines, vaccine carrier-proteins, antibodies, and novel antibody-based proteins.[3] The XpressCF+ platform allows for precise incorporation of non-natural amino acids into a protein sequence, and Sutro is using this technology to develop homogeneous site-specific antibody-drug conjugates (ADCs).[4] Once identified, production of protein drug candidates can be scaled in Sutro's cGMP manufacturing facility located in San Carlos, CA.

Sutro's technology has also contributed to the formation of SutroVax, a vaccine spin off founded in 2015 that has raised over $170 million in capital.[5]

Collaborations

In July 2018, Sutro signed a collaboration and licensing agreement with Merck to discover and develop novel cytokine-based therapies for cancer and autoimmune disorders. Sutro received an upfront payment of $60 million and is eligible for milestone payments totaling up to $1.6 billion associated with the development and sale of all therapeutic candidates and all possible indications identified under the collaboration. In 2017, Sutro and Celgene announced it had refocused its 2014 immuno-oncology collaboration on four programs that are advancing through preclinical development, including an ADC program targeting B-Cell maturation antigen (BCMA).

Awards

The XpressCF Platform was awarded Best ADC Technology Platform at the World ADC in 2018, with Sutro as the runner up for Best New Drug Developer. Sutro was named one of Fierce Biotech's Fierce 15 in 2014.[6] In 2015 was awarded the DiNA Outstanding Partner Award by the California Life Sciences Association.[7]

References
  1. "William J Newell named CEO of Sutro Biopharma".
  2. "About Sutro's technology".
  3. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ (July 2011). "Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines". Biotechnology and Bioengineering. 108 (7): 1570–8. doi:10.1002/bit.23103. PMC 3128707. PMID 21337337.
  4. "Sutro's ADC technology".
  5. "Tilting at vaccines giants, SutroVax fuels up on a $170M-plus quest to vault past the world's best-selling vaccine". Endpoints News. Retrieved 2019-04-25.
  6. "FierceBiotech's 2014 Fierce 15". FierceBiotech. Retrieved 2019-04-23.
  7. "Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony - California Life Sciences Association". California Life Sciences Association. 2015-11-09. Retrieved 2018-11-28.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.